Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

NOX-E36 - A Phase Ib, Multiple Intravenous Dose Study to Evaluate Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties in Healthy Subjects and Then in Three Groups of Patients With Type 2 Diabetes Mellitus to Compare Three Ascending Dose Regimens in a Double-blind and Placebo-controlled Manner

NCT01085292 is registered in ClinicalTrials.gov with TME Pharma AG as lead sponsor.

NCT NCT01085292
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01085292 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
NOX-E36 - A Phase Ib, Multiple Intravenous Dose Study to Evaluate Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties in Healthy Subjects and Then in Three Groups of Patients With Type 2 Diabetes Mellitus to Compare Three Ascending Dose Regimens in a Double-blind and Placebo-controlled Manner
Lead sponsor
TME Pharma AG
Phase
Phase 1/2
Overall status
Completed
Start date
July 31, 2010
Completion date
February 29, 2012
Enrollment
47 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus